CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Allergic rhinitis - How up-to-date is this topic?
Changes
Version 1.1, revision planned in 2012.
Last revised in January 2011
January 2011 — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.
August 2009 — minor update. Xylometazoline 0.05% nasal drops (Otrivine Child Nasal Drops®) are no longer licensed for use in children between 2 and 5 years of age. They can be prescribed for children who are 6 years of age and over. Issued in August 2009.
May 2009 — minor formatting correction. Issued in June 2009.
October 2007 to January 2008 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.
The previous system of classifying a person with allergic rhinitis by the persistence and severity of their symptoms to determine management has been modified. Management is now divided into whether or not a person with symptoms of allergic rhinitis is presently on treatment, and this is reflected in the scenarios offered.
© NHS Institute for Innovation and Improvement